Your browser is no longer supported. Please, upgrade your browser.
EIGR Eiger BioPharmaceuticals, Inc. weekly Stock Chart
EIGR [NASD]
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.10 Insider Own1.00% Shs Outstand24.36M Perf Week42.96%
Market Cap188.04M Forward P/E- EPS next Y-2.16 Insider Trans19.65% Shs Float23.99M Perf Month13.36%
Income-70.30M PEG- EPS next Q-0.80 Inst Own86.00% Short Float4.01% Perf Quarter-45.25%
Sales- P/S- EPS this Y19.30% Inst Trans1.46% Short Ratio2.57 Perf Half Y-21.86%
Book/sh2.32 P/B3.33 EPS next Y-10.20% ROA-62.30% Target Price34.83 Perf Year-46.91%
Cash/sh3.90 P/C1.98 EPS next 5Y- ROE-105.20% 52W Range4.55 - 15.82 Perf YTD-48.19%
Dividend- P/FCF- EPS past 5Y17.00% ROI- 52W High-51.20% Beta1.52
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low69.67% ATR0.78
Employees24 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)53.83 Volatility9.55% 13.49%
OptionableYes Debt/Eq0.00 EPS Q/Q24.30% Profit Margin- Rel Volume0.54 Prev Close7.16
ShortableYes LT Debt/Eq0.54 EarningsMar 19 AMC Payout- Avg Volume373.87K Price7.72
Recom1.00 SMA2025.48% SMA50-13.21% SMA200-29.47% Volume202,073 Change7.82%
Jun-26-19Initiated Citigroup Buy $22
Jan-29-19Initiated Robert W. Baird Outperform $47
May-09-18Initiated B. Riley FBR, Inc. Buy $24
Jan-03-18Initiated Ladenburg Thalmann Buy $32
Oct-19-17Initiated ROTH Capital Buy $35
Jun-21-17Resumed Wedbush Outperform $28 → $34
Apr-09-20 06:08PM  Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals +7.82%
Apr-01-20 04:05PM  Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic PR Newswire -13.24%
Mar-24-20 10:25AM  Eiger Completes NDA Submission of Progeria Drug Lonafarnib Zacks +11.88%
Mar-23-20 08:00AM  Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies PR Newswire +5.37%
Mar-20-20 06:45AM  Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought US$151k Worth Of Shares Simply Wall St.
Mar-13-20 08:00AM  Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire +5.54%
Jan-19-20 03:04PM  Top Insider Buys Highlight for the Week of Jan. 17 GuruFocus.com
Jan-15-20 05:24AM  Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares Simply Wall St.
Jan-07-20 08:00AM  Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer PR Newswire
Jan-06-20 08:00AM  Eiger Updates on 2019 Progress and 2020 Milestones Expected PR Newswire
Dec-16-19 05:15PM  Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies PR Newswire
Dec-07-19 01:33AM  Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
Nov-15-19 08:00AM  Eiger to Present at Jefferies 2019 London Healthcare Conference PR Newswire
Nov-12-19 08:45AM  Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 PR Newswire
Nov-11-19 09:58AM  Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy? Insider Monkey
Nov-07-19 04:05PM  Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update PR Newswire
Oct-21-19 09:00AM  Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019 PR Newswire
Oct-09-19 09:47AM  Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares? Simply Wall St.
Sep-27-19 08:00AM  Eiger to Present at Cantor 2019 Global Healthcare Conference PR Newswire
Aug-29-19 04:05PM  Eiger BioPharmaceuticals to Participate in September Conferences PR Newswire
Aug-20-19 08:00AM  Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection PR Newswire
Aug-08-19 04:05PM  Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update PR Newswire
Aug-05-19 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences in August PR Newswire -6.37%
Jul-31-19 08:00AM  Immunotherapy startup names new CEO American City Business Journals
Jul-18-19 09:20AM  Small Peninsula biotech targets big impact on deadly childhood aging disease American City Business Journals
Jul-11-19 12:42PM  Need To Know: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Insiders Have Been Buying Shares Simply Wall St.
Jul-08-19 09:00AM  What Makes Eiger BioPharma (EIGR) a New Buy Stock Zacks +12.97%
Jun-20-19 07:08PM  Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
Jun-18-19 07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 04:16PM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) PR Newswire
Jun-10-19 08:00AM  Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PR Newswire
Jun-05-19 08:00AM  Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development PR Newswire
May-30-19 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference PR Newswire
May-17-19 04:05PM  Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer PR Newswire
May-09-19 05:04PM  Eiger BioPharma: 1Q Earnings Snapshot Associated Press
04:01PM  Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update PR Newswire
Apr-30-19 08:00AM  Eiger to Present at ChinaBio® Partnering Forum 2019 PR Newswire
Apr-26-19 02:43PM  Do Institutions Own Shares In Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)? Simply Wall St.
Apr-23-19 03:50PM  Weekly CFO Buys Highlight GuruFocus.com
Apr-17-19 10:53PM  Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire -5.72%
04:01PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Apr-15-19 08:00AM  Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PR Newswire
Apr-11-19 04:05PM  Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress 2019 PR Newswire
Mar-26-19 08:00AM  Eiger BioPharmaceuticals to Participate in Conferences in April PR Newswire
Mar-25-19 01:30PM  Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 PR Newswire
Mar-20-19 08:00AM  Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PR Newswire
Mar-15-19 09:04AM  What Makes Eiger BioPharma (EIGR) a New Buy Stock Zacks
Mar-14-19 04:19PM  Eiger BioPharma: 4Q Earnings Snapshot Associated Press
Mar-13-19 08:00AM  Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress 2019 PR Newswire
Mar-11-19 08:00AM  Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit PR Newswire
Mar-08-19 07:37PM  [$$] Five Best: Susan Froderberg on Extraordinary Mountain Ascents The Wall Street Journal
Mar-04-19 07:00AM  Clinigen and Eiger BioPharmaceuticals Launch Worldwide Managed Access Program for Lonafarnib for Patients with Progeria and Progeroid Laminopathies Business Wire
Feb-27-19 08:00AM  Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer PR Newswire
Feb-06-19 08:00AM  Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan PR Newswire
Feb-04-19 08:00AM  Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans PR Newswire
Jan-07-19 08:00AM  Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors PR Newswire +8.79%
Dec-31-18 07:30AM  Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Dec-21-18 09:25AM  Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares? Simply Wall St. -5.62%
Dec-19-18 08:00AM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies PR Newswire -5.34%
Dec-18-18 08:00AM  Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection PR Newswire -5.75%
Dec-17-18 08:00AM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection PR Newswire
Dec-11-18 02:30PM  Eiger BioPharmaceuticals Reports on 2018 R&D Day PR Newswire
Dec-04-18 08:00AM  Eiger BioPharmaceuticals to Host R&D Day in New York City PR Newswire
07:59AM  The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga
Dec-03-18 04:05PM  Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer PR Newswire +5.56%
08:00AM  Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies PR Newswire
Nov-23-18 08:25AM  Analysis: Positioning to Benefit within Artisan Partners Asset Management, Gamco Investors, Eiger BioPharmaceuticals, Waddell & Reed Financial, AmpliPhi Biosciences, and Limbach Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +8.98%
Nov-19-18 08:00AM  Eiger to Participate in Piper Jaffray Healthcare Conference PR Newswire
Nov-09-18 08:23AM  Eiger BioPharma: 3Q Earnings Snapshot Associated Press -6.19%
08:00AM  Eiger Bio Reports Third Quarter 2018 Financial Results PR Newswire
Oct-23-18 09:00AM  Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PR Newswire
08:35AM  The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares Benzinga
Oct-22-18 04:01PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire -10.01%
08:00AM  Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019 PR Newswire
Oct-18-18 08:00AM  Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference PR Newswire
07:56AM  The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs Benzinga
Oct-17-18 04:05PM  Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection PR Newswire +7.36%
08:15AM  The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise Benzinga
Oct-16-18 04:05PM  Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) PR Newswire +7.09%
04:05PM  Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint PR Newswire
Sep-25-18 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences PR Newswire
Sep-24-18 08:00AM  Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 PR Newswire
Aug-27-18 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences PR Newswire
Aug-13-18 08:00AM  Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia PR Newswire
Aug-10-18 08:09AM  Eiger BioPharma: 2Q Earnings Snapshot Associated Press
08:00AM  Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results PR Newswire
Aug-07-18 08:00AM  Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-06-18 08:00AM  Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health PR Newswire
Jul-31-18 08:00AM  Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection PR Newswire
Jul-19-18 07:26AM  Eiger BioPharmaceuticals (EIGR) Enters Oversold Territory Zacks
05:51AM  Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-04-18 08:00AM  Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018 PR Newswire +8.00%
May-30-18 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference PR Newswire
May-24-18 09:05AM  Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PR Newswire -6.09%
08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-23-18 04:15PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
May-18-18 08:10AM  Todays Research Reports on Stocks to Watch: Eiger BioPharmaceuticals and Nektar Therapeutics ACCESSWIRE -17.26%
May-16-18 08:00AM  Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals PR Newswire +8.22%
08:00AM  Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) PR Newswire
May-11-18 08:09AM  Eiger BioPharma: 1Q Earnings Snapshot Associated Press +8.11%
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dietz Thomas JohnDirectorMar 16Buy4.951,0004,95030,000Mar 17 05:17 PM
Glenn Jeffrey SDirectorMar 16Buy5.0330,000150,81366,355Mar 17 05:16 PM
Mayer Eldon C. IIIEx VP & Chief Commerc. OfficerJan 24Buy13.525,00067,60330,000Jan 30 04:44 PM
Dietz Thomas JohnDirectorJan 10Buy13.944,00055,76024,000Jan 13 08:17 AM
Dietz Thomas JohnDirectorApr 23Buy11.105,00055,49520,000Apr 23 06:53 PM
Dietz Thomas JohnDirectorApr 22Buy11.055,00055,25015,000Apr 22 09:34 PM
Ryali SriramChief Financial OfficerApr 22Buy11.081,25013,8531,250Apr 22 09:34 PM
Patton Stephana EileneSee RemarksApr 22Buy11.031,00011,0304,000Apr 22 09:31 PM